Search All Tech Briefings


Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available.  Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 1173 Results

Title
Intervention Indication Therapeutic Area Year Actions
Cemiplimab in combination with chemotherapy for advanced or metastatic non-small cell lung cancer – first-line Cemiplimab (Libtayo; REGN2810) , Ipilimumab (Yervoy; BMS 734016; MDX 101) Non-small-cell lung cancer (NSCLC) Lung and Respiratory Cancer 2021 View  |  Download
Cemiplimab for recurrent, persistent or metastatic cervical cancer – second line Cemiplimab (Libtayo; REGN2810) Cervical cancer Female Reproductive Cancer 2020 View  |  Download
Cemiplimab for advanced cutaneous squamous cell Cemiplimab (Libtayo; REGN2810) Squamous cell carcinoma (SCC) Skin Cancer 2017 View  |  Download
Cemiplimab as a monotherapy for advanced or metastatic non-small-cell lung cancer whose tumours express PD-L1 – first line Cemiplimab (Libtayo; REGN2810) Non-small-cell lung cancer (NSCLC) Lung and Respiratory Cancer 2020 View  |  Download
Ceftobiprole medocaril for treating hospital-acquired pneumonia or community-acquired pneumonia requiring hospitalisation in children Ceftobiprole medocaril Community-acquired pneumonia , Hospital-acquired pneumonia Infectious Disease , Respiratory System 2022 View  |  Download
Cefepime-enmetazobactam for treating hospital-acquired pneumonia including ventilator-associated pneumonia Exblifep (Cefepime;Enmetazobactam) Hospital-acquired pneumonia , Ventilator-associated pneumonia Infectious Disease , Respiratory System 2024 View  |  Download
Cediranib with olaparib for previously treated platinum resistant recurrent ovarian cancer Cediranib (Recentin; AZD2171) , Olaparib (Lynparza; MK-7339; AZD2281; AZD-2281) Ovarian cancer Female Reproductive Cancer 2021 View  |  Download
Cediranib in combination with olaparib for recurrent platinum-resistant ovarian cancer – fourth line or greater Cediranib (Recentin; AZD2171) , Olaparib (Lynparza; MK-7339; AZD2281; AZD-2281) Epithelial ovarian cancer , Fallopian tube cancer , primary peritoneal cancer Female Reproductive Cancer 2019 View  |  Download
CC-486 for maintenance therapy in acute myeloid leukaemia Azacitidine (Vidaza; CC-486) Acute myeloid leukaemia (AML) Haematological Cancer and Lymphomas 2020 View  |  Download
CC-486 for angioimmunoblastic T-cell lymphoma Azacitidine (Vidaza; CC-486) Angioimmunoblastic T-cell Lymphoma (AITL) Haematological Cancer and Lymphomas 2020 View  |  Download
1 2 94 95 96 97 98 117 118
Medicines
Medicine Industry's Gateway to NICE
Support for Industry
Outputs & Publications